Registry of lecanemab treatment for Alzheimer's in Canada

This study tracks the real-world experience of people with early Alzheimer's disease who are already taking lecanemab. It aims to better understand how the medication works and its safety in everyday medical practice.

This study collects real-world safety information from people taking the Alzheimer's drug LEQEMBI (also known as lecanemab). It helps doctors understand how well the medicine works outside of clinical trials and what side effects may occur.

This study tests a new combination treatment (X/T plus X-EC) for people with Alzheimer's who are already taking Leqembi (lecanemab). It aims to see if the new drug is safe and well-tolerated.

This study follows people with Alzheimer's who are already taking Leqembi (lecanemab) after being in the JOY-ALZ study. It collects medical information to check how the treatment works in real-world use.

This study tests whether adding a new drug called lencanizumab to standard Alzheimer's medications can help slow memory loss in people with early Alzheimer's. It's an observational study, meaning you'll receive the treatment as part of your regular care, and researchers will track your progress.

This study looks at how well lecanemab (a new Alzheimer's treatment) works in real-world clinics. It also tracks how patients and their care partners do over time. If you are already getting or eligible for lecanemab, you might join with your care partner.